المؤلفون: Neven, P, Fasching, P A, Chia, S, Jerusalem, Guy, De Laurentiis, M, Im, S-A, Petrakova, K, Bianchi, G V, Martín, M, Nusch, A, Sonke, G S, De la Cruz-Merino, L, Beck, J T, Zarate, J P, Wang, Y, Chakravartty, A, Wang, C, Slamon, D J

المصدر: Breast Cancer Research, 25 (1), 103 (2023-08-31)

مصطلحات موضوعية: Advanced breast cancer, CDK4/6 inhibitor, First line, Overall survival, Ribociclib, Fulvestrant, ribociclib, Humans, Female, Proportional Hazards Models, Postmenopause, Breast Neoplasms/drug therapy, Breast Neoplasms, Oncology, Cancer Research, Human health sciences, Sciences de la santé humaine, Oncologie

العلاقة: urn:issn:1465-5411; urn:issn:1465-542X

الوصول الحر: https://orbi.uliege.be/handle/2268/313198Test

المؤلفون: Neven, P., Fasching, P.A., Chia, S., Jerusalem, G., De, Laurentiis M., Im, S.-A., Petrakova, K., Bianchi, G.V., Martin, M., Nusch, A., Sonke, G.S., De, la Cruz-Merino L., Beck, J.T., Zarate, J.P., Wang, Y., Chakravartty, A., Wang, C., Slamon, D.J.

المساهمون: Im, S.-A.

مصطلحات موضوعية: ABEMACICLIB PLUS, PATIENTS PTS, PALBOCICLIB, THERAPY, LETROZOLE, INTERIM, Advanced breast cancer, CDK4/6 inhibitor, First line, Overall survival, Ribociclib

العلاقة: Breast Cancer Research, Vol.25 No.1, p. 103; https://hdl.handle.net/10371/195837Test; 001055913300001; 2-s2.0-85169355504; 192406

الإتاحة: https://doi.org/10.1186/s13058-023-01701-9Test
https://hdl.handle.net/10371/195837Test

المؤلفون: Slamon, D J, Neven, P, Chia, S, JERUSALEM, Guy, De Laurentiis, M, Im, S, Petrakova, K, Valeria Bianchi, G, Martín, M, Nusch, A, Sonke, G S, De la Cruz-Merino, L, Beck, J T, Ji, Y, Wang, C, Deore, U, Chakravartty, A, Zarate, J P, Taran, T, Fasching, P A

المصدر: Annals of Oncology, 32 (8), 1015-1024 (2021)

مصطلحات موضوعية: CDK4/6 inhibitor, advanced breast cancer, overall survival, ribociclib, Aminopyridines, Purines, Receptors, Estrogen, Receptors, Progesterone, Fulvestrant, ERBB2 protein, human, Receptor, ErbB-2, Adolescent, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Double-Blind Method, Female, Humans, Postmenopause, Breast Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Hematology, Oncology, Human health sciences, Sciences de la santé humaine, Oncologie

العلاقة: https://api.elsevier.com/content/article/PII:S0923753421015532?httpAccept=text/xmlTest; urn:issn:0923-7534; urn:issn:1569-8041

الوصول الحر: https://orbi.uliege.be/handle/2268/292335Test

المؤلفون: Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Bianchi, G. Valeria, Martin, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J. P., Taran, T., Fasching, P. A.

المساهمون: 임석아, Im, S.

مصطلحات موضوعية: DEPENDENT KINASE 4/6, THERAPY, ribociclib, CDK4, 6 inhibitor, advanced breast cancer, overall survival

العلاقة: Annals of Oncology, Vol.32 No.8, pp.1015-1024; 140901; https://hdl.handle.net/10371/177211Test; 000685036900010; 2-s2.0-85109796710

الإتاحة: https://doi.org/10.1016/j.annonc.2021.05.353Test
https://hdl.handle.net/10371/177211Test

المؤلفون: Giulia Val Bianchi, Xavier Pivot, Guy Jerusalem, Luis de la Cruz-Merino, Stephen Chia, Tetiana Taran, Gabe S. Sonke, Seock-Ah Im, Arnd Nusch, Francisco J. Esteva, Patrick Neven, J. Thaddeus Beck, Michelino De Laurentiis, Miguel Martin, Arunava Chakravartty, Dennis J. Slamon, K. Petrakova, Yingbo Wang, Karen Rodriguez-Lorenc, Manu Sondhi, Peter A. Fasching

المساهمون: Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. -A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martin, M., Nusch, A., Sonke, G. S., De La Cruz-Merino, L., Beck, J. T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., Taran, T., Jerusalem, G.

مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.drug_class, Receptor, ErbB-2, Aminopyridines, Ribociclib, Breast Neoplasms, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Drug Administration Schedule, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Overall survival, Humans, 030212 general & internal medicine, Progression-free survival, Fulvestrant, Purine, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Cancer, General Medicine, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, Postmenopause, Aminopyridine, Receptors, Estrogen, Estrogen, Purines, Female, business, Receptors, Progesterone, Breast Neoplasm, medicine.drug, Human

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba7b985d7c2eab2c811a010405df43eTest
http://hdl.handle.net/11588/804127Test